Covelli, Vito, Passeri, Maria Elena, Leogrande, Domenica et al. · Current medicinal chemistry · 2005 · DOI
Quick Summary
This review examines how stress affects both the nervous and immune systems, and explores potential drug treatments for stress-related disorders. The authors discuss how the body's stress response systems can trigger or worsen conditions like chronic fatigue syndrome (CFS), and suggest that medicines targeting immune cell activity and inflammatory chemicals may help. They found that CFS patients have different immune patterns compared to depressed patients, which could guide future treatment approaches.
Why It Matters
This review is relevant to ME/CFS because it proposes that abnormal immune and nervous system interactions contribute to CFS pathophysiology, and identifies potential drug targets for treatment. Understanding these neuroimmune mechanisms may help explain why CFS patients experience fatigue, post-exertional malaise, and other symptoms, and could inform development of targeted therapies.
Observed Findings
Decreased serum interferon-gamma levels detected in CFS patients
Leptin levels remained within normal ranges in CFS individuals, but were elevated in depressed patients used as controls
Phagocytic immune deficits, endotoxemia, and elevated proinflammatory cytokines (TNF-alpha and IL-1 beta) observed in stress-related disorders such as phobic disorders and migraine without aura
Variable immune effects of benzodiazepines: diazepam inhibits immune function while alprazolam enhances immune responses
Beta-blockers and thymic hormone administration produced clinical symptom improvement in stress-related disorders with corresponding immune changes
Inferred Conclusions
Immune cells and proinflammatory cytokine inhibition represent major drug targets in stress-related disorders including CFS
Therapeutic approaches should focus on modulating Th1/Th2 responses and reducing proinflammatory cytokine production
Antidepressants may exert beneficial effects in stress-related conditions through immune mechanisms such as decreased interferon-beta release or augmented natural killer cell activity
Neuroimmune dysfunction involving both nervous and immune system abnormalities contributes to CFS pathogenesis
Remaining Questions
What This Study Does Not Prove
This review does not definitively establish cause-and-effect relationships between immune abnormalities and CFS symptoms, nor does it prove that any specific drug is effective for CFS patients. The evidence cited is observational and from varied study designs; the authors acknowledge that no specific CFS biomarkers have been consistently identified. The review also does not establish whether immune changes are primary drivers of CFS or secondary consequences of the disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
What is the specific etiology and full pathogenic mechanism of CFS?
Which immune-modulating agents (staphypan Berna, lactic acid bacteria, kuibitang, IVIG) are most effective for CFS, and what are their mechanisms of benefit?
Are the immune abnormalities observed in CFS primary causes or secondary consequences of the disease?
How do individual variations in stress response systems and immune phenotypes affect CFS severity and treatment response?